Clients

At The Aequitas Group, we approach each client engagement from a global perspective, taking into consideration the product life cycle and the development or commercialization stage of each product or technology.

In all of the markets that we serve—whether biotechnology, pharmaceutical, medical device, laboratory, or healthcare services—our approach is centered on product evaluation.  We perform in-depth research and analysis to identify and define the current and future market opportunity for each product or technology.  We look at the product life cycle and provide assistance and advice at each stage of development and commercialization through a focused reimbursement strategy.  Through education and training, managed market analysis, and valuable reimbursement strategy and tactics, our goal is to advise our clients about issues that will help them make better decisions and provide the highest level of support and return on their investments.

The Aequitas Group specializes in serving companies in the following spaces:

Pharmaceutical and Biotechnology

In the post-Medicare Modernization Act environment, pharmaceutical and biotechnology manufacturers must balance issues related to the U.S. Food and Drug Administration’s (FDA’s) constrictive criteria and obtain adequate coverage and payment for new and current therapies by U.S. and other world payors. Despite a constrictive FDA environment, the payors are generally agreeable to coverage and payment only if the appropriate outcomes are demonstrated. Although the healthcare markets in the United States and worldwide are dynamic and set to continue to evolve over the next decade, it is still possible to gain appropriate approval and coverage and payment for your therapies if you use the right pathways. The Aequitas Group maintains a staff of proven professionals with experience working in and with the FDA, public and private U.S. payors, and payors and regulatory groups worldwide. Our experts can help maneuver in the regulatory and payor environments to bring your pharmaceuticals and biologics to patients in a timely manner.

Medical Devices

The current medical-device environment faces significant state and federal regulatory hurdles. Despite these difficulties, an ever-growing patient population is demanding and benefiting from these life-saving products. Emerging today are entirely new categories of devices with the potential to fundamentally alter clinical practice. Due to the increasing reliance on medical devices in all phases of patient care, devices provide substantial opportunities to improve quality and efficiency. Despite the value of diagnostics, multiple challenges can inhibit development and adoption of products, such as regulatory and reimbursement hurdles. The Aequitas Group understands the FDA's approach toward classification and regulation of devices. From a reimbursement perspective, The Aequitas Group also understands how the payors value the FDAs assessment of devices via the 510 (k) or pre-market-approval pathways. The Aequitas Group will work with you from clinical trial through device launch and beyond to ensure success for your products in the dynamically changing healthcare markets.

Diagnostics

As the U.S. and worldwide healthcare markets evolve, diagnostics are becoming more “visible” to regulators and payors. Most of the world’s regulators and payors view diagnostic therapies as combination products, to be used in conjunction with various devices, products, or both and not as stand-alone products. The payors are agreeable to coverage and payment only if appropriate outcomes are demonstrated. Although the healthcare markets in the United States and worldwide are dynamic and set to continue to evolve over the next decade, it is still possible to gain approval or recognition for your diagnostic therapy, with the appropriate coverage and payment needed for market acceptance, if you use the right pathways. The Aequitas Group maintains a staff of proven professionals with experience in working in and with the FDA, public and private U.S. payors, and payors and regulatory groups worldwide. We know the significant challenges facing companies that bring needed diagnostics to the marketplace and we can put you on the right pathway to payor coverage and payment.

Reimbursement Call Centers and Patient-Assistance Programs

Now more than ever, reimbursement and patient-assistance vendors face increased competition and increasingly complex customer demands. To succeed and grow their businesses, vendors must focus on becoming true partners with manufacturers, providers, and patients. The Aequitas Group has the experience to turn customer expectations into best-in-class solutions. The Aequitas Group maintains a staff of proven professionals with experience in working for manufacturers, public and private payors, care-delivery systems, and reimbursement-hotline vendors. We have helped reimbursement and patient-assistance vendors strengthen their infrastructure, expand their capabilities, and increase their collaboration with customers. Specifically, we have provided custom solutions in the following areas:

A Select List of The Aequitas Group's Clients 

Abraxis Bioscience
Access Med
Accuray
Aesthera
Allergan
Altheus Therapeutics
Baxter International
Bayer Healthcare
Biogen Idec
BioVex
Boston Scientific
Bristol-Meyers Squibb Company
Calypso Medical
C.R. Bard
Cell Therapeutics
CuraScript
Eisai, Inc.
Fresenius Medical Care
Gilead Sciences
Joint Active Systems
Ligand Pharmaceuticals
Merck and Company
Milestone Pharmaceuticals
NeoMatrix
Neuronetics
Nucletron
Pfizer
Prometheus Laboratories
Quidel Corporation
Roche Pharmaceuticals
Regenesis
RxCrossroads
Sanofi-Aventis
Stiefel Laboratories
US Oncology
Vasomedical
Watson Pharmaceuticals